1)Akaza H, Kameyama S, Koiso K, et al:Analyses of the effects of intravesical Bacillus Calmette-Guerin(Tokyo 172 strain)therapy of superficial bladder cancer. Nippon Hinyokika Gakkai Zasshi 80:167-174, 1989
2)Akaza H, Kameyama S, Kakizoe T, et al:Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group. Nippon Hinyokika Gakkai Zasshi 83:183-189, 1992
3)赤座英之:BCG膀胱内注入療法と副作用.BCG・BRM療法誌23:59-65,1999
4)赤座英之,戸井田一郎,鈴木唯司,他:BCG副作用対応について.他科の判断と治療.泌尿器外科14:311-327,2001
5)Akaza H, Koiso K, Ozono S, et al:PMCJ-9 Study Group in Japan. A clinical study of PMCJ-9(Bacillus Calmette-Guerin Connaught strain)treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J Clin Oncol 33:382-390, 2003
6)Orihuela E, Herr HW, Pinsky CM, et al:Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer 60:326-333. 1987
7)膀注用イムシスト製品情報概要.日本化薬,2003
8)Vegt PD, van der Meijden AP, Sylvester R, et al:Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 157:1246-1249, 1997
9)Lamm DL:Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 19:565-572, 1992